Harding I, Garaud J J
Merrell Dow Research Institute, Egham, Surrey, UK.
J Antimicrob Chemother. 1988 Jan;21 Suppl A:93-103. doi: 10.1093/jac/21.suppl_a.93.
A total of 88 patients were treated with teicoplanin for infections caused by coagulase-negative staphylococci in open clinical studies in France and the UK. Teicoplanin was administered once daily, with a mean dose of 323 mg, for a mean duration of 16 days. Thirty-nine patients received teicoplanin alone while 49 received combination treatment. Clinical cure or improvement occurred in 79 of 82 evaluable cases (96.3%) and bacteriological elimination in 82 cases (95.1%). Treatment with teicoplanin alone was clinically successful in all cases, including 20 septicaemias, and the elimination rate was 93%. There was no apparent correlation between clinical and bacteriological outcomes and results of in-vitro testing. The variation in MICs between France and the UK was attributed to differences in the methods used.
在法国和英国开展的开放性临床研究中，共有88例由凝固酶阴性葡萄球菌引起感染的患者接受了替考拉宁治疗。替考拉宁每日给药1次，平均剂量为323毫克，平均疗程为16天。39例患者单独接受替考拉宁治疗，49例接受联合治疗。82例可评估病例中有79例（96.3%）实现临床治愈或病情改善，82例（95.1%）实现细菌清除。单独使用替考拉宁治疗的所有病例临床均获成功，包括20例败血症，清除率为93%。临床和细菌学结果与体外试验结果之间无明显相关性。法国和英国之间MICs的差异归因于所采用方法的不同。
